New Mexico Game and Fish says viral ‘horned rabbits' possible in the state
Peculiar-looking cotton-tailed rabbits have been popping up in northern Colorado. And although these rabbits may look intimidating, experts say there's no reason to be spooked. 'It looked like a zombie and kind of disturbing,' said Julius Angeli of Albuquerque.
His mother, Eva Angeli, told KRQE News 13 that these rabbits look unreal. 'It looks like something out of science fiction,' she said.
These rabbits are infected with a papilloma virus that produces benign protrusions on a rabbit's or hare's face or head. 'Fortunately, these growths tend to be benign, so, but still, it's definitely out of the ordinary,' explained Darren Vaughan, spokesperson for the New Mexico Department of Game and Fish.
New Mexico Department of Game and Fish to sell nearly 500 leftover deer licenses
He says the growths can impede a rabbit's ability to eat, drink, or move around, but the virus is not contagious. It's transmitted to rabbits from fleas, ticks, or even mosquitoes. 'It is not transmissible to people or other animals. However, that doesn't mean that you shouldn't still take caution,' continued Vaughan.
Vaughan says that although there have been no reports of these infected rabbits in New Mexico so far, it's not something they are ruling out just yet. 'As far as we know, it hasn't made its way into New Mexico yet. But then again, like I said, it could just be that people haven't seen it yet, that it is in fact here,' said Vaughan.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors
New board members bring decades of experience in company building, corporate strategy, drug development, and commercialization across multiple therapeutic areas CAMBRIDGE, Mass., August 19, 2025--(BUSINESS WIRE)--eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the appointment of Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors. Douglas Williams, Ph.D., brings more than 30 years of leadership experience in the biopharmaceutical industry, including senior executive roles at Biogen, ZymoGenetics, Amgen, and Seattle Genetics (now Seagen). He has contributed to the development of several blockbuster therapies, including Enbrel®, Tecfidera® and Spinraza®. Most recently, he served as President of R&D at Sana Biotechnology and as founding CEO of Codiak Biosciences. Dr. Williams currently serves on the boards of Climb Bio (Chair) and CAMP4 Therapeutics. Adam Craig, M.D., Ph.D., is a biotechnology executive with over 25 years of global experience in drug development and commercialization, particularly in oncology, hematology, and rare diseases. He served as President and CEO of CTI BioPharma leading to the approval and commercialization of Vonjo®. He is currently Executive Chairman of X4 Pharmaceuticals and was recently interim CEO of Stratus Therapeutics (formerly Garuda Therapeutics). Dr Craig previously held CMO and senior development roles at Sunesis Pharmaceuticals and Chemgenex Pharmaceuticals and currently serves on the board of Stratus Therapeutics. Dr. Craig is a Member of the Royal College of Physicians (U.K.) and holds medical and doctoral degrees from the University of London, a Ph.D. in Molecular Oncology from Leeds University, and an MBA from the Open Business School. "Doug and Adam are highly accomplished leaders whose deep expertise across R&D, commercialization, and corporate strategy will be invaluable as we advance our development candidates, EGEN-2784 for kidney failure and EGEN-5784 for liver failure, into the clinic," said Michael Curtis, Ph.D., Chief Executive Officer, eGenesis. "Their guidance will be invaluable as we advance into the next phase of growth as a clinical-stage company focused on our mission to transform the treatment of organ failure." "eGenesis is developing truly pioneering solutions for one of the most pressing unmet needs in medicine," said Dr. Williams. "The combination of cutting-edge genetic engineering, rigorous science, and a mission-driven team positions eGenesis to deliver breakthroughs that could fundamentally change the field of organ transplantation." "eGenesis is leading a field with the potential to transform the future of transplantation," added Dr. Craig. "I look forward to supporting the company's mission to develop safe, effective, human-compatible organs that could redefine the treatment of organ failure and offer hope to millions of patients awaiting a transplant." Drs. Williams and Craig join current Board members Steven Gillis, Ph.D. (Board Chairman), Bob More, Fabio Pucci, Ph.D., Brad Smith, Julie Sunderland, and Albert (Al) Wiegman. About eGenesis eGenesis is pioneering a genome engineering-based approach to develop safe, effective transplantable organs to end the global organ shortage. Its platform uniquely addresses cross-species molecular incompatibilities and viral risk via its proprietary genetic engineering platform to improve outcomes for patients in need of a transplant. With demonstrated preclinical success, eGenesis is advancing programs in kidney transplantation, acute liver failure, and heart transplantation. Learn more at Follow us @egenesisbio. View source version on Contacts MediaKimberly Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fast Company
27 minutes ago
- Fast Company
Healthcare docs are the unsung hero of travel season: An estate planning expert and seasoned traveler weighs in
If you've ever felt that jolt of anxiety mid-flight—the kind that hits during unexpected turbulence—you're not alone. I've logged more than 350 flights since founding Trust & Will, and even as a seasoned traveler, there are still moments that shake me. It turns out, I'm not the only one who thinks about mortality somewhere over 30,000 feet. Since launching our estate planning platform in 2017, we've consistently seen a spike in new members and updates to plans right before major holidays and travel weekends. Every July, without fail, we get messages from parents on their way to Europe, newlyweds prepping for a honeymoon, or college grads heading out on post-grad adventures, many of whom start or finish their estate plan in the final hours before boarding. Why? Because travel is a trigger. Not just for excitement, but for reflection—and a little fear. THE OVERLOOKED MVP OF YOUR ESTATE PLAN When most people think about estate planning, they picture a will. Maybe a trust. Maybe funeral wishes. But one of the most important sets of documents often gets overlooked—especially by younger people: healthcare documents. These include your HIPAA authorization, medical power of attorney, and living will (also known as an advance healthcare directive). Collectively, they determine who can speak on your behalf, access your medical info, and make decisions if you're unable to. In other words: They're the playbook for your care when the unexpected happens. DESIGN MEETS INTENTION An estate plan should be frictionless, intuitive, and human. The same design principles that guide app UX or airline check-in flows apply here. The process of choosing a healthcare proxy or outlining medical preferences should feel approachable, not anxiety-inducing. That's why we spent years developing a guided experience that walks people through decisions in plain language. Whether you're sitting at a gate or on a layover, your documents are a tap away and ready to be shared if you're ever in an emergency, especially in rural or international areas where access to care is different. We've heard real stories: A hiking injury in Maui where a traveler needed emergency airlift and care coordination. A solo trip to Europe where a college student got sick and had no legal guardian anymore, but hadn't yet appointed a healthcare agent. These aren't just hypotheticals; they're avoidable moments of chaos if the right documents are in place. QUICK TIPS BEFORE YOUR NEXT TRIP Whether you're a frequent flyer or just headed out for summer vacation, here are three things to do before your next takeoff: Name A Healthcare Proxy: Who do you trust to speak on your behalf if you're unconscious or unable to communicate? This isn't just for the elderly—it's crucial for everyone over 18. Store Your Documents Digitally: Paper is great until you leave it in a hotel drawer. Keep digital copies of your estate and health documents in a secure vault or cloud platform that you can access and share from anywhere. Talk To Your Travel Companions: It might feel awkward, but telling your spouse, partner, or travel buddy where your documents are stored and what your wishes are can make a huge difference in an emergency. A DIFFERENT KIND OF TRAVEL CHECKLIST In the same way you wouldn't travel without your ID or passport, your estate plan—especially your healthcare documents—deserves a spot on your checklist. We spend a lot of time planning our vacations. Booking the right hotel. Earning points for upgrades. Picking restaurants. But the true peace of mind? It doesn't come from TSA PreCheck or an airport lounge. It comes from knowing that if something were to happen, your family isn't left scrambling for answers. That kind of planning? It's the ultimate design of care.
Medscape
27 minutes ago
- Medscape
Air Pollution Exposure May Be Linked to Higher Asthma Risk
TOPLINE: Long-term exposure to ambient air pollutants over 48 months was associated with an increased risk for asthma exacerbation in women, even at low concentrations. Nitrogen dioxide (NO 2 ) showed the strongest association with higher odds of exacerbation. A plant-based diet did not modify these effects. METHODOLOGY: Researchers assessed the associations between 48-month air pollution exposure and asthma exacerbations in the Nurses' Health Study II cohort and examined whether a plant-based diet modifies these relationships. Overall, they analyzed 4326 women (mean age, 43 years; 96.7% White individuals) with physician-diagnosed asthma and medication use during 1997-1998 and 2013-2014 periods. Plant-based diet adherence was evaluated every 4 years using a validated food-frequency questionnaire that categorized intake into 18 groups (12 plant-based and six animal-based) and generated a Plant-Based Diet Index score ranging from 18 to 90. Residential exposures to fine particulate matter (PM 2.5 ), NO 2 , and ozone (O 3 ) were measured over 48-month periods before outcome assessments. ), NO , and ozone (O ) were measured over 48-month periods before outcome assessments. The main outcome was asthma exacerbation was defined as hospital admission, emergency department visits, or urgent care visits due to uncontrolled asthma in the past year, assessed in 1998 and 2014. TAKEAWAY: Median 48-month concentrations of PM 2.5 decreased from 13.7 μg/m 3 in 1993-1997 to 8.9 μg/m 3 in 2009-2013, and those of NO 2 dropped from 12.0 ppb to 6.6 ppb. However, median 48-month concentrations of ozone increased from 25.5 ppb to 27.8 ppb. decreased from 13.7 μg/m in 1993-1997 to 8.9 μg/m in 2009-2013, and those of NO dropped from 12.0 ppb to 6.6 ppb. However, median 48-month concentrations of ozone increased from 25.5 ppb to 27.8 ppb. In adjusted single-pollutant models, higher exposures to PM 2.5 and NO 2 were associated with increased odds of asthma exacerbation (adjusted odds ratio [aOR], 1.43; 95% CI, 1.14-1.80 and aOR, 1.25; 95% CI, 1.12-1.38, respectively). and NO were associated with increased odds of asthma exacerbation (adjusted odds ratio [aOR], 1.43; 95% CI, 1.14-1.80 and aOR, 1.25; 95% CI, 1.12-1.38, respectively). However, in adjusted multipollutant models, higher NO 2 exposure remained significantly associated with an increased risk for asthma exacerbation (aOR, 1.23; 95% CI, 1.06-1.42), whereas higher exposures to PM 2.5 and O 3 were not. exposure remained significantly associated with an increased risk for asthma exacerbation (aOR, 1.23; 95% CI, 1.06-1.42), whereas higher exposures to PM and O were not. No significant interaction was observed between air pollutants and plant-based diet index scores in relation to asthma exacerbation risk (P = .69 for PM 2.5 ; P = .29 for NO 2 ; P = .60 for O 3 ). IN PRACTICE: 'Our results add to growing evidence that supports lowering acceptable standards for key air pollutants and highlights the need to identify personal, modifiable strategies of increasing resilience among susceptible populations, including women with asthma,' the authors wrote. SOURCE: The study was led by Jing Gennie Wang, MD, Division of Pulmonary Critical Care and Sleep Medicine at The Ohio State University Wexner Medical Center in Columbus, Ohio. It was published online on July 28, 2025, in Annals of the American Thoracic Society. LIMITATIONS: The study population consisted predominantly of White female nurses, limiting generalizability. The Plant-Based Diet Index score could not distinguish between whole-food and ultraprocessed plant-based diets, potentially affecting the assessment of diet-pollution interactions. Residential mobility among participants may have introduced some exposure misclassification. DISCLOSURES: The study received funding from the Nurses' Health Study II cohort infrastructure grant and the American Lung Association Early Career Investigator Award. Most authors declared receiving grants from the American Lung Association, and two authors reported receiving financial support from some pharmaceutical organizations. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
